HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
-8.31%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$972M
AUM Growth
+$972M
(-33%)
Cap. Flow
-$367M
Cap. Flow
% of AUM
-37.78%
Top 10 Holdings %
Top 10 Hldgs %
50.21%
Holding
77
New
12
Increased
11
Reduced
25
Closed
20
Top Buys
| 1 |
Hologic
HOLX
|
$27.9M |
| 2 |
Cigna
CI
|
$25.4M |
| 3 |
Eli Lilly
LLY
|
$22.9M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$18.2M |
| 5 |
Agilent Technologies
A
|
$16.4M |
Top Sells
| 1 |
Envista
NVST
|
$44.5M |
| 2 |
AbbVie
ABBV
|
$41.2M |
| 3 |
Teleflex
TFX
|
$35.2M |
| 4 |
Abbott
ABT
|
$31M |
| 5 |
CVS Health
CVS
|
$29M |
Sector Composition
| 1 | Healthcare | 96.07% |
| 2 | Consumer Discretionary | 0% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$20.2B
| $84.4M | 8.48% |
413,640
+11,980
| +3% | +$2.44M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $72.1M | 7.24% |
903,850
+193,740
| +27% | +$15.5M |
|
3
Boston Scientific
BSX
$157B
| $67.4M | 6.77% |
1,807,990
-42,460
| -2% | -$1.58M |
|
4
BioMarin Pharmaceuticals
BMRN
$11.2B
| $61.4M | 6.17% |
740,948
-28,068
| -4% | -$2.33M |
|
5
Centene
CNC
$14.5B
| $45.8M | 4.6% |
540,860
-93,750
| -15% | -$7.93M |
|
6
UnitedHealth
UNH
$283B
| $35M | 3.52% |
68,230
-4,350
| -6% | -$2.23M |
|
7
Natera
NTRA
$23B
| $31.8M | 3.2% |
898,420
-551,116
| -38% | -$19.5M |
|
8
Bristol-Myers Squibb
BMY
$96.1B
| $31.8M | 3.19% |
412,420
-117,740
| -22% | -$9.07M |
|
9
LivaNova
LIVN
$3.08B
| $30.4M | 3.05% |
486,550
-15,800
| -3% | -$987K |
|
|
10
Hologic
HOLX
$14.9B
| $27.9M | 2.8% |
+402,110
| New | +$27.9M |
|
11
Tenet Healthcare
THC
$16.3B
| $27.3M | 2.74% |
518,990
+235,260
| +83% | +$12.4M |
|
|
CCXI
12
DELISTED
ChemoCentryx, Inc.
CCXI
| $27.2M | 2.73% |
1,097,370
+140,630
| +15% | +$3.48M |
|
13
Elevance Health
ELV
$73B
| $26.2M | 2.63% |
54,230
-19,120
| -26% | -$9.23M |
|
|
14
Cigna
CI
$80.7B
| $25.4M | 2.55% |
+96,470
| New | +$25.4M |
|
15
Danaher
DHR
$144B
| $24.6M | 2.47% |
96,880
-610
| -0.6% | -$155K |
|
|
16
Eli Lilly
LLY
$653B
| $22.9M | 2.3% |
+70,630
| New | +$22.9M |
|
17
Cencora
COR
$57.5B
| $22.2M | 2.23% |
156,910
-174,000
| -53% | -$24.6M |
|
18
Humana
HUM
$37.6B
| $22.1M | 2.22% |
47,220
-61,820
| -57% | -$28.9M |
|
|
19
Abbott
ABT
$230B
| $21.7M | 2.18% |
199,300
-285,440
| -59% | -$31M |
|
|
RVNC
20
DELISTED
Revance Therapeutics, Inc.
RVNC
| $19.6M | 1.97% |
1,418,088
-5,337
| -0.4% | -$73.8K |
|
21
Henry Schein
HSIC
$8.33B
| $19.1M | 1.92% |
248,920
-6,310
| -2% | -$484K |
|
22
Cytokinetics
CYTK
$5.8B
| $19.1M | 1.92% |
485,600
-649,510
| -57% | -$25.5M |
|
|
SGEN
23
DELISTED
Seagen Inc. Common Stock
SGEN
| $18.2M | 1.83% |
+103,060
| New | +$18.2M |
|
24
Incyte
INCY
$17B
| $17.8M | 1.79% |
234,130
-266,270
| -53% | -$20.2M |
|
25
Syndax Pharmaceuticals
SNDX
$1.4B
| $17.8M | 1.79% |
923,400
-257,100
| -22% | -$4.95M |
|